<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80517">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01791647</url>
  </required_header>
  <id_info>
    <org_study_id>000102011</org_study_id>
    <nct_id>NCT01791647</nct_id>
  </id_info>
  <brief_title>Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>Myo-inositol Versus Metformin: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <authority>Italy: Catholic University of Sacred Heart</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effects of six months treatment of two
      insulin-lowering therapies on the clinical and endocrine-metabolic parameters in obese women
      affected by polycystic ovary syndrome. The study group includes 40 patients, randomly
      allocated to subgroup A (metformin 1500 mg/day) and subgroup B (myo-inositol 1500 mg/day).
      The investigations include menstrual pattern and hirsutism score evaluation, hormonal
      assays, oral glucose tolerance test, euglycemic hyperinsulinaemic clamp and lipid profile at
      baseline and after six months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of cycles</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>effects of two therapies on glyco-insulinemic metabolism</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the curve insulin post oral glucose tolerance test (Î¼UI/ML/180min), M value of euglycemic hyperinsulinaemic clamp(mg/kg/min).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>myo-inositol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1500 mg/day myoinositol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1500 mg/day of metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin 1500 mg</intervention_name>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>myoinositol 1500 mg</intervention_name>
    <arm_group_label>myo-inositol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with Polycystic Ovary Syndrome, diagnosed in accordance with Rotterdam
             Consensus Conference Criteria 2003;

          -  BMI&gt;25 kg/m2;

          -  age 18-35 years.

        Exclusion Criteria:

          -  pregnancy;

          -  significant liver or renal impairment;

          -  other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for
             the clinical signs);

          -  neoplasms;

          -  unstable mental illness;

          -  diagnosis of diabetes mellitus or impaired glucose tolerance;

          -  use of drugs able to interfere with gluco-insulinaemic metabolism for at least three
             months prior to entering the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Lanzone, Professor</last_name>
    <phone>063057794</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Guido, Medical Doctor</last_name>
      <phone>063057794</phone>
    </contact>
    <investigator>
      <last_name>Maurizio Guido, Medical Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 12, 2013</lastchanged_date>
  <firstreceived_date>March 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Maurizio Guido</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>myoinositol</keyword>
  <keyword>metformin</keyword>
  <keyword>glucose-insulinemic metabolism</keyword>
  <keyword>menstrual pattern</keyword>
  <keyword>insulin-lowering therapies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
